^
BIOMARKER:

BCAT1 expression

i
Other names: BCAT1, Branched Chain Amino Acid Transaminase 1, Branched-Chain-Amino-Acid Aminotransferase, Cytosolic, Branched Chain Aminotransferase 1, Cytosolic, BCT1, Branched Chain Amino-Acid Transaminase 1, Cytosolic, Placental Protein 18, Protein ECA39, PNAS121, BCAT(C), MECA39
Entrez ID:
10d
The present results indicated that curcumin may induce apoptosis by inhibiting the BCAT1 and mTOR pathways. Thus, understanding the mechanism underlying curcumin‑induced apoptosis in cytarabine‑resistant cells can support the development of novel drugs for leukemia.
Journal
|
BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
BCAT1 expression
|
cytarabine
1m
Indeed, we found BCAT1 KD cells to be particularly sensitive to topoisomerase inhibitors such as etoposide...Genetic depletion of BCAT1 slows tumor growth in vivo and renders cells particularly sensitive to topoisomerase inhibitors. Our results identify BCAT1 as a novel therapeutic target and suggest that a combination of BCAT1 inhibitor and topoisomerase inhibitor could be particularly useful in BCAT1 overexpressing T-ALL cases.
NOTCH1 (Notch 1) • BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
NOTCH1 mutation • NOTCH1 expression • BCAT1 expression • NOTCH1 overexpression
|
etoposide IV
2ms
This study revealed miR-98 inhibits gastric cancer cell stemness and chemoresistance by targeting BCAT1, suggesting that this miR-98/BCAT1 axis represents a potential therapeutic target in gastric cancer.
Journal
|
CD44 • BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
BCAT1 expression • CD44 expression
|
cisplatin • paclitaxel
3ms
Chromatin immunoprecipitation assays demonstrated that c‑Myc has binding sites in the GLUT1 promoter. Collectively, the present findings suggested that BCAT1 is upregulated in human HNSCC and regulates HNSCC cell proliferation, invasion, cisplatin sensitivity and c‑Myc/GLUT1 signaling.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
MYC overexpression • BCAT1 expression
|
cisplatin
3ms
Our results revealed that FLOT2 promotes NPC cell proliferation by suppressing miR-33b-5p, to maintain proper levels of c-Myc, and upregulate BCAT1trancription. Therefore, the FLOT2/miR-33b-5p/c-Myc/BCAT1 axis is a potential therapeutic target for NPC.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
MYC expression • BCAT1 expression
4ms
Moreover, inhibition of autophagy by chloroquine increased cisplatin sensitivity in vivo. Also, the knockdown of BCAT1 or the administration of leucine activated mTOR signaling, inhibited autophagy, and increased cisplatin sensitivity in cancer cells in vivo. These findings demonstrate a new mechanism, revealing that BCAT1 decreases cisplatin sensitivity in cancer cells by inducing mTOR-mediated autophagy via branched-chain amino acid leucine metabolism, providing an attractive pharmacological target to improve the effectiveness of chemotherapy.
Journal
|
BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
BCAT1 expression
|
cisplatin • chloroquine phosphate
5ms
Additionally, BCAT1 correlated with apoptosis, hypoxia and angiogenesis processes in gliomas and high expression of BCAT1 revealed higher glycolysis level and increased immunosuppressive status in tumor progression. We concluded that BCAT1 is a strong prognostic factor for glioma patients and involved in the malignant progression of IDH1 wild-type gliomas.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ATRX (ATRX Chromatin Remodeler) • BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
IDH1 mutation • BCAT1 expression
5ms
[Conclusion] CAT1 functioned as an infection receptor, interacting with BLV particles. These findings provide insights for BLV infection and for developing new strategies for treating BLV and preventing its spread.
BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
BCAT1 expression
6ms
In summary here we have demonstrated for the first time that BCAT1 expression protects against pro‐oxidant treatment whilst increasing vulnerability standard therapeutic treatment. This data opens up a new therapeutic avenue for clinicians seeking novel strategies in the stratified treatment of BCAT1high and BCAT1low expressing patients.
BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
BCAT1 expression
|
cytarabine
10ms
Furthermore, silencing of LINC00324 reversed the promoting effects of BCAT1 on the proliferation, migration, and invasion of GC cells. Silencing of LINC00324 inhibited the proliferation, migration, and invasion of GC cells through regulating the miR-3200-5p/BCAT1 axis.
Journal
|
BCAT1 (Branched Chain Amino Acid Transaminase 1 ) • MIR3200 (MicroRNA 3200) • MIR320A (MicroRNA 320a)
|
BCAT1 expression
12ms
BCAT1 and CD133 can be considered as biomarkers with prognostic significance for TNBC.
Journal
|
CD133 • BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
BCAT1 expression
12ms
Taken together, our data demonstrated that Six1 was upregulated in human thyroid cancers and promoted cell proliferation and invasion. Our data also revealed new roles of Six1 in thyroid cancer development by modulating glucose metabolism and invasion, possibly through regulation of Snail, MMP2 and GLUT3.
Journal
|
MMP2 (Matrix metallopeptidase 2) • BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
BCAT1 expression
1year
In summary, our data showed that BCAT1 was overexpressed in human NSCLCs. BCAT1 facilitated cell proliferation and invasion possibly through regulation of the Wnt signaling pathway.
Journal
|
CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • BCAT1 (Branched Chain Amino Acid Transaminase 1 ) • MMP7 (Matrix metallopeptidase 7)
|
MYC expression • CCND1 expression • CDH1 expression • BCAT1 expression
1year
In summary here we have demonstrated for the first time that BCAT1 expression protects against pro‐oxidant treatment whilst increasing vulnerability standard therapeutic treatment. This data opens up a new therapeutic avenue for clinicians seeking novel strategies in the stratified treatment of BCAT1high and BCAT1low expressing patients.
BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
BCAT1 expression
|
cytarabine
1year
Withdrawal of ERG245 restored intracellular lactate levels without reversing the metabolic reprogramming of the cells. We propose that these are elements of a mechanism that links temporal inhibition of BCAT1 to the rise of highly energetic CD8+ T cells with increased cytotoxicity and proliferative capacity in vitro and in vivo.
PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • BCAT1 (Branched Chain Amino Acid Transaminase 1 )
|
CD8 expression • BCAT1 expression
|
ERG 245
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our